Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Callagy, Grace M ^a   Webber, Mark J ^a   Pharoah, Paul D P ^b   Caldas, Carlos ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MEDLINE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SAMPLE SIZE; ADULT; AGE DISTRIBUTION; AGED; BREAST TUMOR; FEMALE; GENETICS; INCIDENCE; META ANALYSIS; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 45949097829     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-153     Document Type: Article

References (63)

1. Galea MH Blamey RW Elston CE Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22(3):207-219. 10.1007/BF01840834 1391987
2. Elston CW Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x 1757079
3. Caldas C Aparicio SA: The molecular outlook. Nature 2002, 415(6871):484-485. 10.1038/415484a 11831227
4. Goldhirsch A Glick JH Gelber RD Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998, 90(21):1601-1608. 10.1093/jnci/90.21.1601 9811309
5. Eifel P Axelson JA Costa J Crowley J Curran WJ Jr. Deshler A Fulton S Hendricks CB Kemeny M Kornblith AB Louis TA Markman M Mayer R Roter D: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001, 93(13):979-989. 10.1093/jnci/93.13.979 11438563
6. Ravdin PM Siminoff LA Davis GJ Mercer MB Hewlett J Gerson N Parker HL: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001, 19(4):980-991. 11181660
7. Fitzgibbons PL Page DL Weaver D Thor AD Allred DC Clark GM Ruby SG O'Malley F Simpson JF Connolly JL Hayes DF Edge SB Lichter A Schnitt SJ: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124(7):966-978. 10888772
8. van't Veer LJ Dai H van de Vijver MJ He YD Hart AA Mao M Peterse HL van der Kooy K Marton MJ Witteveen AT Schreiber GJ Kerkhoven RM Roberts C Linsley PS Bernards R Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536. 10.1038/415530a 11823860
9. Wang Y Klijn JG Zhang Y Sieuwerts AM Look MP Yang F Talantov D Timmermans M Meijer-van Gelder ME Yu J Jatkoe T Berns EM Atkins D Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679. 15721472
10. Eden P Ritz C Rose C Ferno M Peterson C: "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004, 40(12):1837-1841. 10.1016/ j.ejca.2004.02.025 15288284
11. Naderi A Teschendorff AE Barbosa-Morais NL Pinder SE Green AR Powe DG Robertson JF Aparicio S Ellis IO Brenton JD Caldas C: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 2007, 26(10):1507-1516. 10.1038/sj.onc.1209920 16936776
12. Teschendorff AE Naderi A Barbosa-Morais NL Pinder SE Ellis IO Aparicio S Brenton JD Caldas C: A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 2006, 7(10):R101. 1794561 17076897 10.1186/gb-2006-7-10-r101
13. Bogaerts J Cardoso F Buyse M Braga S Loi S Harrison JA Bines J Mook S Decker N Ravdin P Therasse P Rutgers E van't Veer LJ Piccart M: Gene signature evaluation as a prognostic tool: Challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006, 3(10):540-551. 10.1038/ ncponc0591 17019432
14. SpaTano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006, 7(4):347-350. 17092406
15. Perou CM Sorlie T Eisen MB van de Rijn M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Fluge O Pergamenschikov A Williams C Zhu SX Lonning PE Borresen-Dale AL Brown PO Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093 10963602
16. Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB van de Rijn M Jeffrey SS Thorsen T Quist H Matese JC Brown PO Botstein D Eystein Lonning P Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874. 58566 11553815 10.1073/pnas.191367098
17. Blenkiron C Goldstein LD Thorne NP Spiteri I Chin SF Dunning MJ Barbosa-Morais NL Teschendorff AE Green AR Ellis IO Tavare S Caldas C Miska EA: MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol 2007, 8(10):R214. 2246288 17922911 10.1186/gb-2007-8-10-r214
18. Callagy G Cattaneo E Daigo Y Happerfield L Bobrow LG Pharoah PD Caldas C: Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003, 12(1):27-34. 10.1097/ 00019606-200303000-00004 12605033
19. Nielsen TO Andrews HN Cheang M Kucab JE Hsu FD Ragaz J Gilks CB Makretsov N Bajdik CD Brookes C Neckers LM Evdokimova V Huntsman DG Dunn SE: Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004, 64(1):286-291. 10.1158/0008-5472.CAN-03-1242 14729636
20. Makretsov NA Huntsman DG Nielsen TO Yorida E Peacock M Cheang MC Dunn SE Hayes M van de Rijn M Bajdik C Gilks CB: Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004, 10(18 Pt 1):6143-6151. 10.1158/1078-0432.CCR-04-0429 15448001
21. Callagy GM Pharoah PD Pinder SE Hsu FD Nielsen TO Ragaz J Ellis IO Huntsman D Caldas C: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006, 12(8):2468-2475. 10.1158/1078-0432.CCR-05-2719 16638854
22. McDonnell TJ Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991, 349(6306):254-256. 10.1038/349254a0 1987477
23. McDonnell TJ Troncoso P Brisbay SM Logothetis C Chung LW Hsieh JT Tu SM Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52(24):6940-6944. 1458483
24. Pietenpol JA Papadopoulos N Markowitz S Willson JK Kinzler KW: Vogelstein B Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994, 54(14):3714-3717. 8033089
25. McShane LM Altman DG Sauerbrei W Taube SE Gion M Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97(16):1180-1184. 16106022
26. Kroger N Milde-Langosch K Riethdorf S Schmoor C Schumacher M Zander AR Loning T: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006, 12(1):159-168. 10.1158/1078-0432.CCR-05-1340 16397038
27. Sirvent JJ Aguilar MC Olona M Pelegri A Blazquez S Gutierrez C: Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. Histol Histopathol 2004, 19(3):759-770. 15168338
28. Chang J Clark GM Allred DC Mohsin S Chamness G Elledge RM: Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. Cancer 2003, 97(3):545-553. 10.1002/ cncr.11083 12548595
29. Yang Q Sakurai T Yoshimura G Suzuma T Umemura T Nakamura M Nakamura Y Mori I Kakudo K: Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 2003, 10(1):121-125. 12469156
30. Kymionis GD Dimitrakakis CE Konstadoulakis MM Arzimanoglou I Leandros E Chalkiadakis G Keramopoulos A Michalas S: Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?. J Surg Res 2001, 99(2):161-168. 10.1006/jsre.2001.6084 11469882
31. Jalava PJ Collan YU Kuopio T Juntti-Patinen L Kronqvist P: Bcl-2 immunostaining: A way to finding unresponsive postmenopausal N+ breast cancer patients. Anticancer Res 2000, 20(2B):1213-1219. 10810424
32. Mottolese M Benevolo M Del Monte G Buglioni S Papaldo P Nistico C Di Filippo F Vasselli S Vici P Botti C: Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol 2000, 126(12):722-729. 10.1007/ PL00008478 11153146
33. Le MG Mathieu MC Douc-Rasy S Le Bihan ML Adb El All H Spielmann M Riou G: C-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 1999, 84(6):562-567. 10.1002/ (SICI)1097-0215(19991222)84:6<562::AID-IJC4>3.0.CO;2-0 10567899
34. Berardo MD Elledge RM de Moor C Clark GM Osborne CK Allred DC: Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998, 82(7):1296-1302. 10.1002/ (SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.0.CO;2-1 9529021
35. Sjostrom J Krajewski S Franssila K Niskanen E Wasenius VM Nordling S Reed JC Blomqvist C: A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 1998, 78(6):812-815. 9743306
36. Zhang GJ Tsuda H Adachi I Fukutomi T Yamamoto H Hirohashi S: Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 1997, 27(6):371-377. 10.1093/jjco/27.6.371 9437997
37. Elledge RM Green S Howes L Clark GM Berardo M Allred DC Pugh R Ciocca D Ravdin P O'Sullivan J Rivkin S Martino S Osborne CK: Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol 1997, 15(5):1916-1922. 9164202
38. Silvestrini R Benini E Veneroni S Daidone MG Tomasic G Squicciarini P Salvadori B: P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996, 14(5):1604-1610. 8622078
39. Hellemans P van Dam PA Weyler J van Oosterom AT Buytaert P Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995, 72(2):354-360. 7640218
40. Gasparini G Barbareschi M Doglioni C Palma PD Mauri FA Boracchi P Bevilacqua P Caffo O Morelli L Verderio P: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995, 1(2):189-198. 9815973
41. Silvestrini R Veneroni S Daidone MG Benini E Boracchi P Mezzetti M Di Fronzo G RilkA F Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994, 86(7):499-504. 10.1093/jnci/86.7.499 8133533
42. Parmar MK Torri V Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834. 10.1002/ (SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 9921604
43. Lee WY Su WC Lin PW Guo HR Chang TW Chen HH: Expression of S100A4 and Met: Potential predictors for metastasis and survival in early-stage breast cancer. Oncology 2004, 66(6):429-438. 10.1159/000079496 15452371
44. Lipponen P Pietilainen T Kosma VM Aaltomaa S Eskelinen M Syrjanen K: Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995, 177(1):49-55. 10.1002/path.1711770109 7472779
45. Charpin C Garcia S Bonnier P Martini F Andrac L Horschowski N Lavaut MN Allasia C: Bcl-2 automated quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up. J Clin Oncol 1998, 16(6):2025-2031. 9626199
46. Kapranos N Karaiosifidi H Valavanis C Kouri E Vasilaros S: Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res 1997, 17(4A):2499-2505. 9252670
47. McCallum M Baker C Gillespie K Cohen B Stewart H Leonard R Cameron D Leake R Paxton J Robertson A Purdie C Gould A Steel M: A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004, 90(10):1933-1941. 10.1038/sj.bjc.6601826 15138474
48. Veronese S Mauri FA Caffo O Scaioli M Aldovini D Perrone G Galligioni E Doglioni C Dalla Palma P Barbareschi M: Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up. Int J Cancer 1998, 79(1):13-18. 10.1002/ (SICI)1097-0215(19980220)79:1<13::AID-IJC3>3.0.CO;2-Z 9495351
49. Bhatavdekar JM Patel DD Shah NG Vora HH Suthar TP Chikhlikar PR Ghosh N Trivedi TI: Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: A multivariate analysis. Ann Surg Oncol 2000, 7(4):305-311. 10.1007/s10434-000-0305-5 10819372
50. Al-Moundhri M Nirmala V Al-Mawaly K Ganguly S Burney I Rizvi A Grant C: Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003, 9(4):226-231. 14688828
51. Abdulkader I Sanchez L Cameselle-Teijeiro J Gude F Chavez JE Lopez-Lopez R Forteza J Fraga M: Cell-cycle-associated markers and clinical outcome in human epithelial cancers: A tissue microarray study. Oncol Rep 2005, 14(6):1527-1531. 16273250
52. Linjawi A Kontogiannea M Halwani F Edwardes M Meterissian S: Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004, 198(1):83-90. 10.1016/j.jamcollsurg.2003.08.008 14698315
53. Koukourakis MI Giatromanolaki A Galazios G Sivridis E: Molecular analysis of local relapse in high-risk breast cancer patients: Can radiotherapy fractionation and time factors make a difference?. Br J Cancer 2003, 88(5):711-717. 10.1038/sj.bjc.6600755 12618880
54. DerSimonian R Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2 3802833
55. Higgins JP Thompson SG Deeks JJ Altman DG: Measuring inconsistency in meta-analyses. Bmj 2003, 327(7414):557-560. 192859 12958120 10.1136/ bmj.327.7414.557
56. Egger M Davey Smith G Schneider M Minder C: Bias in meta-analysis detected by a simple, graphical test. Bmj 1997, 315(7109):629-634. 2127453 9310563
57. Zinkel S Gross A Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006, 13(8):1351-1359. 10.1038/sj.cdd.4401987 16763616
58. Carroll JS Meyer CA Song J Li W Geistlinger TR Eeckhoute J Brodsky AS Keeton EK Fertuck KC Hall GF Wang Q Bekiranov S Sementchenko V Fox EA Silver PA Gingeras TR Liu XS Brown M: Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38(11):1289-1297. 10.1038/ng1901 17013392
59. Feldman M Stanford R Catcheside A Stotter A: The use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer. Eur J Surg Oncol 2002, 28(6):615-619. 10.1053/ ejso.2002.1300 12359196
60. Blamey RW Ellis IO Pinder SE Lee AH Macmillan RD Morgan DA Robertson JF Mitchell MJ Ball GR Haybittle JL Elston CW: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007, 43(10):1548-1555. 10.1016/ j.ejca.2007.01.016 17321736
61. Daidone MG Luisi A Veneroni S Benini E Silvestrini R: Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999, 6(1):61-68. 10.1677/erc.0.0060061 10732789
62. Wang TT Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995, 55(12):2487-2489. 7780952
63. Cardoso F Paesmans M Larsimont D Durbecq V Bernard-Marty C Rouas G Dolci S Sotiriou C Piccart MJ Di Leo A: Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer 2004, 5(5):364-369. 15585074